Loading...
Please wait, while we are loading the content...
Similar Documents
Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study.
| Content Provider | Europe PMC |
|---|---|
| Author | Nagao, Shoji Tamura, Jun Shibutani, Takashi Miwa, Maiko Kato, Tomoyasu Shikama, Ayumi Takei, Yuji Kamiya, Natsuko Inoue, Naoki Nakamura, Kazuto Inoue, Aya Yamamoto, Koji Fujiwara, Keiichi Suzuki, Mitsuaki |
| Abstract | IntroductionThree randomized controlled trials have resulted in extremely extensive application of the strategy of using neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) for patients with advanced epithelial ovarian cancer in Japan. This study aimed to evaluate the status and effectiveness of treatment strategies using NAC followed by IDS in Japanese clinical practice.Patients and methodsWe conducted a multi-institutional observational study of 940 women with Federation of Gynecology and Obstetrics (FIGO) stages III–IV epithelial ovarian cancer treated at one of nine centers between 2010 and 2015. Progression-free survival (PFS) and overall survival (OS) were compared between 486 propensity-score matched participants who underwent NAC followed by IDS and primary debulking surgery (PDS) followed by adjuvant chemotherapy.ResultsPatients with FIGO stage IIIC receiving NAC had a shorter OS (median OS: 48.1 vs. 68.2 months, hazard ratio [HR]: 1.34; 95% confidence interval [CI] 0.99–1.82, p = 0.06) but not PFS (median PFS: 19.7 vs. 19.4 months, HR: 1.02; 95% CI: 0.80–1.31, p = 0.88). However, patients with FIGO stage IV receiving NAC and PDS had comparable PFS (median PFS: 16.6 vs. 14.7 months, HR: 1.07 95% CI: 0.74–1.53, p = 0.73) and OS (median PFS: 45.2 vs. 35.7 months, HR: 0.98; 95% CI: 0.65–1.47, p = 0.93).ConclusionsNAC followed by IDS did not improve survival. In patients with FIGO stage IIIC, NAC may be associated with a shorter OS. |
| Related Links | https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC10232639&blobtype=pdf |
| ISSN | 13419625 |
| Journal | International Journal of Clinical Oncology [Int J Clin Oncol] |
| Volume Number | 28 |
| DOI | 10.1007/s10147-023-02329-7 |
| PubMed Central reference number | PMC10232639 |
| Issue Number | 6 |
| PubMed reference number | 37140771 |
| e-ISSN | 14377772 |
| Language | English |
| Publisher | Springer Nature Singapore |
| Publisher Date | 2023-05-04 |
| Publisher Place | Singapore |
| Access Restriction | Open |
| Rights License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2023 |
| Subject Keyword | Neoadjuvant chemotherapy Epithelial ovarian cancer Adjuvant chemotherapy Interval debulking surgery Primary debulking surgery |
| Content Type | Text |
| Resource Type | Article |
| Subject | Hematology Surgery Oncology |
